Advancing translational immunology in HIV-associated cryptococcal meningitis

Editorial

Peter R Williamson. J Infect Dis. 2013.

. 2013 Jun 15;207(12):1793-5.

doi: 10.1093/infdis/jit102. Epub 2013 Mar 14.

No abstract available

Keywords: Africa; Cryptococcus neoformans; HIV/AIDS; fungus; immunology; meningitis.

Comment on

The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis.
Jarvis JN, Casazza JP, Stone HH, Meintjes G, Lawn SD, Levitz SM, Harrison TS, Koup RA. Jarvis JN, et al. J Infect Dis. 2013 Jun 15;207(12):1817-28. doi: 10.1093/infdis/jit099. Epub 2013 Mar 14. J Infect Dis. 2013. PMID: 23493728 Free PMC article. Clinical Trial.

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525–30. - PubMed
1. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008;47:123–30. - PubMed
1. Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2012;54:121–8. - PubMed
1. Rhein J, Boulware D. Prognosis and management of cryptococcal meningitis in patients with human immunodeficiency virus infection. Neurobehav HIV Med. 2012;4:45–61.
1. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45:76–80. - PubMed